PIK3CA and colorectal carcinoma: BYL719 was selected as a combination agent with abemaciclib against HT-29, Caco-2, and SNU-C4 cell survival to identify the effect of selective PI3K p110α inhibition according to the PIK3CA mutation status of the CRC cell lines.